Mark Hanson is a senior managing director in Evercore’s strategic advisory business.
Mr. Hanson has more than 25 years of experience advising companies across all healthcare sectors, with a focus on technology, services, and life sciences tools & diagnostics.
Recent transactions include advising Athenahealth on its sale to Hellman & Friedman and Bain Capital; Vocera Communications on its sale to Stryker; Inovalon on its sale to Nordic Capital; GE on its acquisition of BK Medical; Parexel International on its sale to EQT and Goldman Sachs Asset Management; Nuance Communications on its sale to Microsoft; Decipher Biosciences on its sale to Veracyte; Leonard Green & Partners on its investment in WellSky; Seniorlink on its sale to Thomas H. Lee Partners; QGenda on the sale of a stake to ICONIQ Capital; Enclara Healthcare on its sale to Humana; Kelsey-Seybold Clinic on its sale to TPG; Centene on numerous acquisitions and divestitures, including WellCare; Aetna on its sale to CVS Health; Humana on the acquisitions of Kindred Healthcare and Curo Health Services; UPMC on Via Oncology and Evolent Health; and Thermo Fisher Scientific on numerous acquisitions and divestitures, including Life Technologies.
For the 10 years prior to joining Evercore in 2014, Mr. Hanson was a managing director at Barclays and Lehman Brothers, leading the life sciences tools and healthcare services team. He began his career at Merrill Lynch.
He earned a B.A. in economics and mathematics from St. Olaf College and an MBA from the Tuck School at Dartmouth College.